Literature DB >> 2162948

Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals.

J G Barnhill1, D J Greenblatt, L G Miller, A Gaver, J S Harmatz, R I Shader.   

Abstract

Male CD-1 mice (age 6 weeks, 6 months, 1 and 2 years) received single 2-mg/kg i.p. doses of clonazepam. Plasma and cortex clonazepam concentrations, rotarod ataxia and in vivo benzodiazepine receptor occupancy were measured at multiple times up to 14 hr after dosage. Elimination of clonazepam from plasma and cortex became slower with age, but cortex concentrations always exceeded those in plasma. The mean ratio was 1.82, and was not influenced by age. Rotarod ataxia was quantitatively greater and of longer duration in aging animals. This was not explained entirely by kinetic changes, as ataxia at any given cortex clonazepam concentration or degree of receptor occupancy was greater in 1-year-old animals than in those age 6 weeks or 6 months. In a second study, 6-week and 1-year-old animals were tested at a fixed time (1 hr) after variable doses of clonazepam (0.01-2.0 mg/kg); findings were consistent with results from the fixed-dose study. In vitro studies evaluated benzodiazepine receptor binding, chloride channel binding and muscimol-stimulated chloride uptake in cortical membrane preparations from animals of the four age groups. Binding affinity and number of binding sites were not influenced by age, or was gamma-aminobutyric acid-dependent muscimol-stimulated chloride uptake (either with or without addition of lorazepam) significantly related to age. Thus, increased overall sensitivity of aging animals to the central depressant effects of clonazepam is evident in the described model.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162948

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

2.  The gamma subunits of the native GABAA/benzodiazepine receptors.

Authors:  Z U Khan; A Gutiérrez; C P Miralles; A L De Blas
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

Review 3.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 4.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

5.  Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men.

Authors:  Joel O Olubodun; Hermann R Ochs; Lisa L von Moltke; Ronenn Roubenoff; Leah M Hesse; Jerold S Harmatz; Richard I Shader; David J Greenblatt
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

6.  Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.

Authors:  A M Stijnen; I Postel-Westra; M W Langemeijer; A Hoogerkamp; R A Voskuyl; C F van Bezooijen; M Danhof
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

Review 7.  Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

Authors:  B E Laurijssens; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 8.  Anesthesia of the geriatric equine.

Authors:  Reza Seddighi; Thomas J Doherty
Journal:  Vet Med (Auckl)       Date:  2012-08-03

9.  Clonazepam-associated Bradycardia in a Disabled Elderly Woman with Multiple Complications.

Authors:  Hidetomo Maruyoshi; Natsue Maruyoshi; Motone Hirosue; Komei Ikeda; Masaaki Shimamoto
Journal:  Intern Med       Date:  2017-08-10       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.